Skip to main content
. Author manuscript; available in PMC: 2020 Dec 1.
Published in final edited form as: Arthritis Rheumatol. 2019 Nov 1;71(12):2059–2067. doi: 10.1002/art.41020

Table 3.

High baseline KL-6 predicts progression of ILD based on the course of the FVC and DLCO over 1 year in patients randomized to CYC and MMF.

Variable Estimate 95% CI P-Value
Outcome: Course of FVC over 12 months in CYC arm

Intercept 9.99 7.02 12.26 0.001
KL-6 −0.32 −0.50 −0.11 0.024
Baseline FVC 0.88 0.87 0.90 <0.001
Time 0.10 0.028 0.17 0.004

Outcome: Course of FVC over 12 months in MMF arm

Intercept 16.92 12.12 21.99 <0.001
KL-6 −0.72 −1.03 −0.32 0.005
Baseline FVC 0.85 0.80 0.89 <0.001
Time 0.054 −0.015 0.12 0.128

Outcome: Course of DLCO over 12 months in CYC arm

Intercept 18.11 14.63 20.60 <0.001
KL-6 −1.30 −1.51 −1.00 <0.001
Baseline DLCO 0.85 0.84 0.87 <0.001
Time −0.024 −0.12 0.076 0.634

Outcome: Course of DLCO over 12 months in MMF arm

Intercept 23.80 17.42 26.21 0.001
KL-6 −1.28 −1.46 −0.84 0.004
Baseline DLCO 0.80 0.78 0.84 <0.001
Time 0.030 −0.051 0.11 0.428